The estimated Net Worth of Holger Wesche is at least $2 Milione dollars as of 1 July 2021. Holger Wesche owns over 10,000 units of Harpoon Therapeutics stock worth over $1,446,225 and over the last 5 years he sold HARP stock worth over $0. In addition, he makes $557,025 as Chief Scientific Officer at Harpoon Therapeutics.
Holger has made over 9 trades of the Harpoon Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of HARP stock worth $6,000 on 1 July 2021.
The largest trade he's ever made was exercising 10,000 units of Harpoon Therapeutics stock on 1 July 2021 worth over $6,000. On average, Holger trades about 5,385 units every 42 days since 2020. As of 1 July 2021 he still owns at least 62,852 units of Harpoon Therapeutics stock.
You can see the complete history of Holger Wesche stock trades at the bottom of the page.
Dr. Holger Wesche Ph.D. serves as Chief Scientific Officer of the Company. He served as our Senior Vice President of Research, and from April 2015 to January 2017, he served as our Vice President of Research. From March 2013 to April 2015, Dr. Wesche was a Scientific Director at Amgen, a biopharmaceutical company, where he was responsible for cross-functional organization and coordination of the next generation BiTE platform, a T cell engaging antibody platform. Dr. Wesche’s experience has focused on target validation, drug discovery and drug development as well as multi-site project management in the fields of oncology and inflammation, and he has led several drug discovery projects through pre-clinical development. Dr. Wesche is also the co-author of numerous publications and several U.S. patents. Dr. Wesche holds an M.S. equivalent in Biochemistry, Biophysical Chemistry and Immunology and earned a Ph.D. equivalent for his work on the IL-1 receptor complex, each from the University of Hannover in Germany.
As the Chief Scientific Officer of Harpoon Therapeutics, the total compensation of Holger Wesche at Harpoon Therapeutics is $557,025. There are 2 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.
Holger Wesche is 52, he's been the Chief Scientific Officer of Harpoon Therapeutics since 2018. There are 12 older and 2 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt e Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: